DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for large cell lung carcinoma — screening already-approved drugs against its 48-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleLarge cell lung carcinoma maps to a 48-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Structures already discussed alongside large cell lung carcinoma in the retrieved literature, rendered from public PubChem SMILES. Which drugs appear here reflects the evidence found, not a ranked prediction.
Molecular view
KIT kinase domain — Sunitinib has a real, experimentally solved structure in complex with this target (PDB 3G0E, 1.6 Å). This is the drug's own deposited structure, not a prediction, and confirms it is a structurally characterised molecule rather than an untested guess.
Loading structure…
helix sheet b49drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3G0E · 1.6 Å · ligand Sunitinib (B49). Experimental structure, not a prediction.
What the evidence adds up to
Large cell carcinoma of the lung is a distinct and highly aggressive form of lung cancer. A retrospective review of 96 consecutive patients admitted to Emory University Hospital over 10 years found that only 10 patients presented with stage I lesions favourable for resection; the remainder were treated primarily with irradiation or chemotherapy. Mean survival for clinical stage I patients was 15.9 months, for stage IIIA patients 7.9 months, for stage IIIB patients 7.1 months, and for stage IV patients 5.8 months. Only one patient survived for 5 years. The authors concluded that this cancer is most commonly seen at an advanced stage and is associated with an unusually dismal prognosis regardless of the method of treatment employed.
A ten-year survey of 713,043 primary lung malignancies diagnosed between 1985 and 1995 in the United States reported an overall 10-year relative survival rate of 7% for all lung cancer patients. For non-small cell histologies, 5-year survival for American Joint Committee on Cancer Stage I surgical patients was greater than 50%. The survey noted a shift toward more complete staging but no change in the distribution of staged cases, and fewer patients in 1995 received cancer-directed treatment compared with earlier periods. The authors stated that the overall poor survival points to a continuing need for improved prevention and treatment measures.
For small cell lung cancer, a 2017 review noted that initial treatment with radiotherapy and chemotherapy produces a high remission rate, but the disease is susceptible to drug resistance and relapse. Treatment for relapsed small cell lung cancer remains a difficult clinical problem, and research is focused on clinical trials of new drug development, optimisation of chemotherapy regimens, and targeted drug development. A 2009 review of other treatment methods stated that despite huge developments in knowledge of cancer, treatment for lung cancer remains firmly rooted in surgery, radiotherapy, and chemotherapy, and that newer, more cancer-targeted agents are making only some inroads into palliative treatments of non-small cell lung cancer.
What is still missing are prospective trials specifically for large cell carcinoma, which is often grouped with other non-small cell histologies, making its distinct behaviour and treatment response difficult to isolate. Adequate funding for such trials, better patient stratification by histologic subtype, and effective strategies to overcome drug resistance in relapsed disease remain absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Cancer · 1999 · 263 citations · open access
Ten-year survey of lung cancer treatment and survival in hospitals in the United States
AbstractBACKGROUND: Primary lung cancer accounts for approximately 14% of all new cancers and 28% of cancer deaths in the U.S. Previous reviews have shown limited progress in the management or outcome of this devastating disease. METHODS: Reports described in the current study were 713,043 primary lung malignancies diagnosed between 1985 and 1995 and submitted to the National Cancer Data Base. Demographic, tumor, and treatment patterns for 1995 were compared with those for 1985-1987, 1988-1991, and 1992-1994. Ten-year relative survival rates were presented for selected demographic and histologic groups and 5-year relative survival rates were presented by stage and dominant treatment modalities for major carcinoma histologies. RESULTS: Previously observed demographic trends were evident, with increasing proportions of patients being older, female, and African American, and more cases reported to be adenocarcinomas. There was a substantial shift toward more complete staging but no change in the distribution of staged cases. Compared with earlier patients, fewer 1995 patients received cancer-directed treatment. More surgical patients underwent lymph node dissection, and radiation treatment was supplemented more often with chemotherapy. The overall 10-year relative survival rate was 7%. The 5-year survival for American Joint Committee on Cancer Stage I surgical patients was >50% for all nonsmall cell histologic groups. CONCLUSIONS: Recent shifts in treatment, although minimal, are consistent with current literature concerning the effectiveness of lung carcinoma treatment. The authors believe that the overall poor survival of lung carcinoma patients points to a continuing need for improved prevention and treatment measures. The comparatively superior survival of Stage I nonsmall cell lung carcinoma surgical patients indicates that a substantial number of patients have the potential to be treated successfully.
Medical Sciences · 2024 · 13 citations · open access
Efficacy of Sorafenib-Based Therapies for Non-Small Cell Lung Cancer
AbstractLung cancer remains the leading cause of cancer-related deaths, with a poor prognosis. Of the two types, non-small cell lung cancer (NSCLC) is the major and most prevalent type and associated with low response rates to the current treatment options. Sorafenib, a multitargeted tyrosine kinase inhibitor used for various malignancies, gained attention for its potential efficacy in NSCLC. This review paper focuses on the findings of recent in vitro, in vivo, and clinical studies regarding the efficacy of sorafenib. Overall, sorafenib has shown definitive therapeutic potential in NSCLC cell lines, xenografts, and human subjects. Novel approaches to sorafenib delivery may improve its efficacy and should be the focus of further studies.
[Advances in the Treatment of Relapsed Small Cell Lung Cancer].
AbstractSmall cell lung cancer (SCLC) is a highly malignant tumor. The initial treatment of radiotherapy and chemotherapy are more sensitive, high remission rate, but susceptible to drug resistance and relapse after treatment. Although the treatment of lung cancer has undergone enormous changes in recent years, treatment for relapsed SCLC is still a difficult problem in clinical field. In view of the serious resistance of recurrent SCLC to the existing chemotherapeutic drugs, the research on recurrent SCLC around the world is focused on the clinical trial of new drug development, optimization of chemotherapy regimen and target drug development. This paper summarize and estimate studies and literature reports of chemotherapy and precision therapy for relapsed SCLC, hopefully it could help clinicians treat relapsed SCLC and give us clinical research direction for relapsed SCLC in the future.
Korean Management Science Review · 2008 · 0 citations
Implementation of a BPMS-based Virtual Enterprise in the Port Logistics Industry
AbstractA retrospective review was made of 96 consecutive patients with large cell carcinoma of the lung admitted to Emory University Hospital over 10 years. Only 10 patients were seen with stage I lesions favorable for resection. The remainder were treated primarily with irradiation or chemotherapy. Mean survival for clinical stage I patients was 15.9 months; stage IIIA patients, 7.9 months; stage IIIB patients, 7.1 months; and stage IV patients, 5.8 months. Only 1 patient survived for 5 years. This distinct and highly aggressive form of lung cancer most commonly is seen at an advanced stage and is associated with an unusually dismal prognosis regardless of the method of treatment employed.
AbstractAbstract There are a number of treatments aimed at destroying cancer locally. They are not routine practice and are used in very carefully selected cases, usually in specialist centres. Despite huge developments in our knowledge of cancer, treatment for lung cancer remains firmly rooted in surgery, radiotherapy, and chemotherapy. Newer, more cancer-targeted agents are making some inroads into the palliative treatments of non-small cell lung cancer, but new approaches continue to be needed. All of the following approaches have their pros and cons and none is widely available.
Sunitinib in patients with refractory NSCLC: Primary results from China.
Abstracte18145 Background: Sunitinib, a small molecule, is a multitargeted receptor kinase inhibitor which targets the vascular endothelial growth factor receptor and platelet-derived growth factor receptor as well as several others. Several clinical trial results have already demonstrated the therapeutic potential of this agent in renal cell carcinoma and gastrointestinal stromal tumor, however, only few studies were conducted to investigate the effectiveness of the use of sunitinib in refractory NSCLC. We reported a case series of patients with previously treated, refractory non-small cell lung cancer and evaluated the clinical activity and tolerability of sunitinib. Methods: Patients with stage IIIb or IV NSCLC for whom platinum-based chemotherapy had failed received sunitinib at a dose of 37.5 mg orally once daily combination with or without standard agents or regimens currently used in the NSCLC. Results: We illustrated 24 refractory NSCLC patients who received sunitinib treatment. Two patients were treated with pemetrexed besides sunitinib, two other patients were treated sunitinib in combination with gemcitabine and gefitinib respectively. Other 20 patients received sunitinib as a single agent. The starting dose of sunitinib was 37.5 mg/d. eight patients who received sunitinib achieved a confirmed objective response. The response rate was 33.3% (8/24). Seven patients showed stable disease. Disease control rate is 62.5% (15/24). Night patients showed progressive disease. PFS ranged from 4 weeks to 18 weeks. mPFS for this study is 4 moths. 1 year survival rate is still follow up. The most commonly AEs (grade 3-4) included fatigue/asthenia (45.8%, 11/24), dry skin (25%, 5/24), and hand-foot syndrome 29.1% (7/24). Other AEs (grade 3-4) were thrombocytopenia, anemia and diarrhea. Conclusions: Sunitinib, as a single agent or in combination with chemotherapy, was well generally tolerated and showed substantial activity in refractory lung cancer. High-quality prospective studies are needed to be conducted. No significant financial relationships to disclose.
Expert Review of Anticancer Therapy · 2015 · 0 citations
Efficacy of crizotinib inhibiting specific molecular pathways in non-small-cell lung carcinoma
AbstractThe US FDA granted approval for crizotinib as the first-line treatment for patients with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase rearranged metastatic non-small-cell lung cancer, on November 20, 2013. Crizotinib is a customized and improved therapeutic option for patients with non-small-cell lung cancer that enhances overall survival without increasing toxicity. In the future, new targeted therapies may achieve additional indications for treating patients with lung cancer. This article summarizes data from crizotinib studies.
Muller Journal of Medical Sciences and Research · 2017 · 0 citations · open access
Crizotinib in treatment of lung cancer
AbstractLung cancer is one of the most common malignancies and is the leading cause of cancer-related mortality throughout the world. Despite advances in surgery and chemotherapy, survival is still poor. Crizotinib is an oral inhibitor of multiple kinases, including anaplastic lymphoma kinase (ALK), and is indicated in the treatment of patients with locally advanced or metastatic? non small cell lung carcinoma (NSCLC) harboring ALK mutation as a targeted therapy. This is short drug review of crizotinib in the treatment of advanced lung cancer.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
